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Vascular endothelial cells (ECs) are important for maintaining vascular homeostasis. Dysfunction of ECs
contributes to cardiovascular diseases, including atherosclerosis, and can impair the healing process
during vascular injury. An important mediator of EC response to stress is the GTPase Rac1. Rac1 responds
to extracellular signals and is involved in cytoskeletal rearrangement, reactive oxygen species generation
and cell cycle progression. Rac1 interacts with effector proteins to elicit EC spreading and formation of
cell-to-cell junctions. Rac1 activity has recently been shown to be modulated by glutathiolation or
S-nitrosation via an active site cysteine residue. However, it is not known whether other redox signaling
compounds can modulate Rac1 activity. An important redox signaling mediator is the electrophilic lipid,
15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2). This compound is a downstream product of cyclooxygenase
and forms covalent adducts with speciﬁc cysteine residues, and induces cellular signaling in a pleiotropic
manner. In this study, we demonstrate that a biotin-tagged analog of 15d-PGJ2 (bt-15d-PGJ2) forms an
adduct with Rac1 in vitro at the C157 residue, and an additional adduct was detected on the tryptic
peptide associated with C178. Rac1 modiﬁcation in addition to modulation of Rac1 activity by bt-15d-
PGJ2 was observed in cultured ECs. In addition, decreased EC migration and cell spreading were observed
in response to the electrophile. These results demonstrate for the ﬁrst time that Rac1 is a target for 15d-
PGJ2 in ECs, and suggest that Rac1 modiﬁcation by electrophiles such as 15d-PGJ2 may alter redox sig-
naling and EC function.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Ras-Related C3 Botulinum Toxin Substrate 1 (Rac1) is a small
GTP hydrolyzing (GTPase) protein in the Ras superfamily. Rac1 is
ubiquitously expressed in many cell types, and regulation is both
dynamic and contextual. Previous studies have described Rac1
dysregulation as a contributing factor in an array of different
pathologies including cardiovascular disease and cancer [1–4].B.V. This is an open access article
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iversity of Alabama at
h Street South, Birmingham,Dysregulation of Rac1 in endothelial cells (ECs) may be important
in disease initiation and progression during cardiovascular disease.
Many studies have shown that Rac1 functions downstream of
many cell surface receptors and is a major pathway by which ECs
migrate and align in the direction of ﬂow [5]. In addition, the
modulation of EC migration is of interest in vascular restenosis,
where normal EC migration and function are necessary for vas-
cular repair after balloon angioplasty and stenting [6]. However,
the mechanisms by which Rac1 can be dysregulated by vascular
oxidative stress, and therefore contribute to vascular injury, are
not clear.
Rac1 acts downstream of G-protein coupled receptors (such as
those for sphinogosine-1-phosphate and stromal cell-derived
factor-1) and tyrosine kinase receptors (such as those for vascular
endothelial growth factor and basic ﬁbroblastic growth factor) and
plays a major role in endothelial cell function [7–10]. Similar to
other Ras GTPase proteins, Rac1 cycles between an active (GTP-
bound) form and an inactive (GDP-bound) form, acting as a mo-
lecular switch dependent on the protein’s GTP/GDP bound stateunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the cytoplasm. Upon binding to GTP, Rac1 undergoes structural
changes which allow for the interaction with cell type- speciﬁc
effector proteins to elicit cellular responses. Rac1 nucleotide
binding is mediated by three families of regulatory proteins in-
cluding guanine exchange factors, guanine activating proteins, and
guanine nucleotide dissociation inhibitors [12]. In addition to nu-
cleotide binding, intracellular localization of Rac1 can impact the
interaction of Rac1 with its effector proteins near the plasma
membrane [13]. Plasma membrane localization is mediated via
post-translational modiﬁcations of Rac1 including lipidation of
cysteine residues. Like other members of the Rho family, Rac1 is
lipidated at C189 by the 20-carbon geranylgeranyl group [14,15].
Additionally, the 16-carbon palmitoylation of Rac1 was recently
described at C178; this lipidation dynamically regulates the loca-
lization of the protein to detergent resistant domains within the
plasma membrane [16].
Since the discovery of Rac1, there has been growing interest in
the ability of Rac1 to regulate and respond to the cellular reductive
and oxidative (redox) environment. Such interest has stemmed
from Rac1's direct interactions with enzymes involved in reactive
species production and regulation, such as NADPH oxidase, nitric
oxide synthase (NOS), and superoxide dismutase 1 (SOD1) [17].
Interestingly, a redox sensitive C18 in the GTP-binding pocket of
Rac1 has been described to regulate its activity via both one
electron or two electron oxidation mechanisms, via either a thiyl
radical-dependent or as most recently described via S-glutathio-
nylation-dependent mechanism [18,19].
An important redox signaling mediator produced during in-
ﬂammation is the cyclopentenone prostanoid, 15-deoxy-Δ12,14-
prostaglandin J2 (15d-PGJ2). This lipid is electrophilic and forms
covalent adducts with speciﬁc cysteine residues, thereby mediat-
ing cellular signaling in a pleiotropic manner [20,21]. 15d-PGJ2 has
been described to accumulate in human atherosclerotic plaques
and promote anti-inﬂammatory pathways. A well-described target
of 15d-PGJ2 is the Kelch-like ECH-associated protein 1 (Keap1)
which regulates the cytoprotective transcription factor nuclear
factor-erythroid 2-related factor 2 (Nrf2) [22,23]. Interestingly,
15d-PGJ2 has been observed to have biphasic effects in many cell
types including ECs, and up-regulates reactive oxygen species [24].
In particular, 15d-PGJ2 has been shown to inhibit migration in
endothelial cells [25]. Since Rac1 can be redox-regulated and
contributes to migration, we sought to determine whether Rac1 is
a cellular target of 15d-PGJ2. In particular, this work explores the
site speciﬁc modiﬁcation of Rac1 by 15d-PGJ2 in vitro and suggests
a correlation between Rac1 modiﬁcation and the inhibition of
migration and spreading in endothelial cells. Furthermore, this
study highlights some important concepts regarding redox sig-
naling by electrophiles and the role of the target proteins involved
in electrophile dependent modulation of biological responses.Materials
Primary bovine aortic endothelial cells (BAEC) were collected as
previously described [26], or purchased (Lonza, Walkersville, MD).
All chemicals were of analytical grade and purchased from Sigma-
Aldrich (St. Louis, MO) unless otherwise noted.Methods
Recombinant Rac1 reactions with bt-15d-PGJ2
Recombinant Rac1 (rRac1) protein was prepared as previously
described [27]. Biotin tagged 15d-PGJ2 (bt-15d-PGJ2) wassynthesized and puriﬁed as previously described [28]. rRac1 con-
sisted of residues 1–192 (non-lipidated or cleaved). The protein
was stored in 50% glycerol at 20 °C. rRac1 thiols were reduced
with 1 mM DTT for 30 min on ice. DTT was removed by dialysis
against a Chelex 100 resin (Bio-Rad)-treated buffer solution con-
taining 50 mM Tris–HCl pH 7.5, 150 mM sodium chloride, 50 mM
GDP, and 50 mM MgCl2 (UltraPure) used for subsequent reactions
and assays. The protein concentration of the dialyzed rRac1 was
measured by BCA protein assay. Equimolar amounts of rRac1 were
reacted with increasing molar ratios of bt-15d-PGJ2 (0:1 to 5:1,
lipid:protein) for 1 h at room temperature. This was 30 fmols
(fmol) of Rac1 with 0.15, 30, or 150 fmol of bt-15d-PGJ2 in a total
volume of 100 ml. Unreacted bt-15d-PGJ2 was quenched using β-
mercaptoethanol (β-ME) at a ﬁnal concentration of 10 mM. Bioti-
nylated lipid adducts on rRac1 were detected either by western
blot or mass spectrometry as described below.
Mass spectrometry of rRac1 adducts
Approximately 1 mg of rRac1 treated with increasing amounts
of bt-15d-PGJ2 was denatured, reduced, then digested using se-
quencing grade trypsin (Promega, Madison, WI). Digested peptides
were loaded onto a self-prepared 11-cm,100-mm-diameter pulled
tip packed with Jupiter 5-mm C18 reversed-phase beads (Phe-
nomenex, Torrance, CA). Samples were analytically separated via
nanoLC by use of an Eksigent MicroAS autosampler and 2D LC
nanopump (Eksigent, Dublin, CA) via two different methods. For
each method, tryptic peptides were separated by liquid chroma-
tography using a gradient of acetonitrile containing 0.2% formic
acid and eluted tryptic peptides were electrosprayed at 2 kV into a
dual linear quadrupole ion trap Orbitrap Velos (Orbitrap) mass
spectrometer (Thermo Fisher Scientiﬁc, San Jose, CA). In the ﬁrst
method samples were analyzed making use of collision-induced
dissociation (CID), and in the other method, samples were ana-
lyzed using high-energy collision dissociation (HCD) for the MS/
MS scans. Brieﬂy, the mass spectrometer was set to switch be-
tween an Orbitrap full scan (m/z 300–1800) followed by successive
MS/MS scans of the 10 or 15 most abundant precursor ions (parent
ions). The dynamic exclusion setting was set to exclude ions for
2 min after a repeat count of three within a 45 s duration. Thermo
Xcalibur RAW ﬁles were converted to mzXML ﬁles using the
converter ReAdW program, then to. MGF ﬁles with the trans-
proteomic pipeline tools software suite. For identiﬁcation of rRac1
the search engines TurboSEQUEST (Thermo, Fisher Scientiﬁc) and
MASCOT 2.2 (Matrix Biosciences). SEQUEST and MASCOT searches
used the latest available UniRef100 database. Parent ion mass ac-
curacy window was set to 10.0 ppm. For rRac1 modiﬁcation by bt-
15d-PGJ2 the search included the mass addition of 626.387 Da on a
cysteine residue. SEQUEST searches were processed and visualized
using Scaffold (Proteome software Inc., Portland, OR) with the
addition of searching with X!Tandem on the Scaffold software.
Manual validation of parent ions was aided by the online program
Protein prospector (MS-product feature) to produce lists of
daughter ions for select peptides and modiﬁed peptides. Cysteine
containing peptides were searched for as non-modiﬁed peptides,
carboxyamidomethyl cysteine (CAM; iodoacetamide treatment
results in the addition of monoisotopic mass 57.021 to Cys), and
bt-15d-PGJ2 (addition of 626.387 to Cys).
Cell culture
BAEC were cultured in Dulbecco's modiﬁed Eagle's medium
(DMEM, Cellgro, Herndon, VA) containing 10% fetal bovine serum
(FBS, Atlanta Biologicals, Atlanta, GA) and supplemented with
5.6 mM D-glucose, 4 mM glutamine and 100 μ/ml penicillin and
100 mg/ml streptomycin (Gibco, Grand Island, NY). Cells were used
S.B. Wall et al. / Redox Biology 4 (2015) 346–354348between passage 5 and 9 and were cultured in 6-well plates to
conﬂuency. For treatments, media was replaced with low-serum
DMEM (0.5% FBS) for 16 h prior to addition of either 15d-PGJ2 or
bt-15d-PGJ2, as described previously [29]. Treatment with lipid is
expressed as a concentration but may be converted to amount
lipid per cell, since in all experiments 2 ml of media is used in
6-well plates with conﬂuent BAEC; we estimate that, the treat-
ment of 10 mM bt-15d-PGJ2 is equivalent to approximately
20 fmol/cell in our conditions. Unless noted otherwise, cells were
washed once prior to treatment with ice cold phosphate buffered
saline (PBS) and lysed with RIPA lysis buffer [50 mM Tris–HCl,
pH 7.4, 0.5% w/v sodium deoxycholate, 0.1% w/v SDS, 150 mM
NaCl, 1 mM ethylenediamine tetraacetic acid (EDTA), and 1% v/v
NP-40), and protease inhibitor cocktail (PIC, Roche Diagnostics,
Indianapolis, IN). Lysates were cleared by centrifugation at 16,862g
unless noted otherwise. Protein concentrations were measured by
DC Lowry protein assay (BioRad, Hercules, CA) adapted for mi-
croplates. Cell viability was measured by lactate dehydrogenase
release assay as previously described [30].
Biotin afﬁnity precipitation
Afﬁnity precipitation of biotin was performed using Neu-
travidin resin. Brieﬂy, BAEC were treated at various times and
concentrations of bt-15d-PGJ2 as described in the results. After
treatment, BAEC were lysed and cleared by centrifugation. Ap-
proximately, 25 ml settled resin (50 ml of 50% slurry; Thermo Sci-
entiﬁc) was used for each experiment and was loaded into Micro
Bio-Spin columns (Bio-Rad, Hercules, CA). The resin was equili-
brated with RIPA buffer prior to loading protein according to the
concentration of bt-15d-PGJ2 (see Table S2 for resin load in-
formation). Volumes were adjusted with RIPA lysis buffer to nor-
malize protein concentration to 1 mg/ml and incubated overnight
at 4 °C on a shaker. Resin was washed six times with 200 ml vo-
lumes of RIPA lysis buffer. Resin was transferred to a fresh tube in
three volumes of 200 ml RIPA and allowed to settle by gravity, and
supernatant was removed. Bound proteins were eluted by heating
at 80 °C for 10 min in 1.5 fold volume of 2 sample buffer (0.1 M
Tris–HCl, 4% SDS, 10% Glycerol, 0.2% Bromophenol blue, pH 6.8,
containing 2% β-mercaptoethanol) on settled resin by heating at
80 °C for 10 min. Within 5 min after heating, resin was brieﬂy
centrifuged and supernatants were collected to a fresh tube for
analysis by SDS-PAGE or stored at 20 °C for later analysis.
Rac1 activity assay
A plasmid encoding a glutathione-S-transferase fusion protein
with Rac1 p21 protein binding domain (GST-PBD) was a generous
gift from Dr. Rakesh Patel (University of Alabama at Birmingham),
and protein was expressed and puriﬁed as previously described
[31]. The Rac1 activity assay was performed based as previously
described with minor changes [32]. Brieﬂy, BAEC were grown to
80% conﬂuence and media replaced with low-serum DMEM (0.5%
FBS) for 16 h prior to treatment with 7.5 mM bt-15d-PGJ2. At in-
dicated time points, cells were washed once with PBS and lysed
with 100 ml per well of Rac activity lysis buffer [50 mM Tris
(pH 7.4), 150 mM NaCl, 0.5% NP-40, 10% glycerol, 1 mM phe-
nylmethylsulfonyl ﬂuoride (PMSF), and PIC] for 5 min. Samples
were collected and centrifuged at 10,000g for 5 min. Lysate (80 ml)
was added to 25 mg of GST-PBD and 20 ml of 50% glutathione
agarose (GSH-A) slurry. This mixture was incubated for 30 min at
4 °C on a shaker. GSH-A was washed with 40 ml (4 times volume of
the settled resin) lysis buffer three times. After the ﬁnal wash,
active Rac1 was eluted from GSH-A with 10 ml of 2 sample buffer
with β-ME. The total 2 ml including resin was loaded onto a 12.5%
SDS-PAGE gel and 2 ml of each reserved 20 ml of comparable lysatewas loaded as an input control to compare to the eluate. For ne-
gative and positive controls, respectively, GDP (1 mM) or non-
hydrolyzable GTP (γ-S-GTP; 0.1 mM) was added to the pre-cleared
lysates and processed the same as all samples. To calculate percent
active Rac1, western blot pixel density of the 21 kDa GST-PBD
eluted Rac1 (active Rac1) was expressed as a percentage of total
Rac1 in the input (total Rac1 in lysate).
Cell migration assay
Cell migration was assessed as previously described [33].
Brieﬂy, BAEC were grown to 80% conﬂuence in 6-well plates.
Media was replaced with low-serum DMEM (0.5% FBS) for approx.
16 h. A sterile pipet tip was used to form 4 cell-free zones in a hash
tag pattern into the conﬂuent monolayer of cells. Media was im-
mediately changed to fresh low-serum DMEM to remove ﬂoating
cells and debris, and cells were treated with the indicated con-
centrations of 15d-PGJ2 or ethanol vehicle control for 4 h before
the cell media was changed to fresh low-serum media; following
this, cells were allowed 4 additional hours to continue migrating
(8 h total migrating time). The width of the cell-free zone was
measured immediately after scratching for an initial measurement,
and again after 8 h at 37 °C in order to allow cell migration. The
migratory ability of the lipid treated cells into the cell-free zone
was expressed as percent change in the width of the scratch
compared to the vehicle controls at 8 h (relative motility).
Cell spreading assay
Cells were seeded at a density of 2105 cells/well and allowed
to reach 70–80% conﬂuence in 10% serum DMEM. Media was
changed to low-serum DMEM (0.5% FBS) for 16 h, then cells were
treated with bt-15d-PGJ2 or EtOH vehicle for 4 h. Cells were de-
tached by 0.05% Trypsin (Gibco, Grand Island, NY) for 3 min, fol-
lowed by neutralization of trypsin with 1 ml of DMEM (10% FBS).
Cells were pelleted and resuspended in DMEM (10% FBS). Cells
were replated at a threefold dilution and were evaluated after both
30 min and 2 h. For each condition, 4 images were acquired and
analyzed by counting the total number of cells per ﬁeld
(10 magniﬁcation), and the number of cells spread/ﬁeld. Data
are expressed as cells spread (%) and values were calculated as
(number of cells spread/total number of cells)100.
Western blot analysis
For all lysate samples, protein concentrations were measured
via Lowry, DC and loaded by equal protein amounts onto 12.5%
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred to nitrocellulose. Transferred protein and amount loaded
was conﬁrmed with Ponceau S stain. Membranes were blocked
with 5% nonfat milk in TBS-T. Rac1 antibody (Millipore, Billerica,
MA) or β-actin antibody (Cell Signaling) was used at a dilution of
1:3000 or 1:5000, respectively, in 0.5% milk TBS-T. Anti-mouse
IgG-HRP (Amersham, Amersham, UK) secondary was used at
1:10,000 in TBS-T for Rac1 and Anti-rabbit IgG-HRP (Amersham)
secondary antibody was used at 1:10,000 in TBS-T for β-actin. In
order to detect biotin, blots were incubated with 10 ml of Strep-
tavidin-HRP (1:10,000 in TBS-T) for 1 h. HRP-conjugated signal
was visualized via chemiluminescence using SuperSignal West
Dura (Thermo Scientiﬁc, San Jose, CA), detected using a FluorChem
M camera imaging system (ProteinSimple). Protein bands were
quantiﬁed by analysis of pixel density using Alpha ViewSA version
3.4.0 software (ProteinSimple, San Jose, CA).
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Data are reported as mean7S.E.M. and sample sizes indicated
in the legends. Statistical signiﬁcance was evaluated by either
standard two-tailed student t-test or via one-way or two-way
ANOVA (analysis of variance) among the groups using Graph pad
(version 5.0). The minimum level of signiﬁcance was set at
po0.05. The least signiﬁcant difference (LSD) test was used as a
post hoc test for the signiﬁcant difference among the groups.Results
Determination of Rac1 modiﬁcation by 15d-PGJ2 in vitro
In order to follow modiﬁcation of proteins by 15d-PGJ2, a bio-
tin-tagged analog (bt-15d-PGJ2) was used. The chemical structure
is shown in Fig. 1A. The tagged analog consists of the parent 15d-
PGJ2 molecule, a linker region and a biotin tag. Bt-15d-PGJ2 forms
covalent adducts to cysteine residues via the two electrophilicFig. 1. Modiﬁcation of recombinant Rac1 by biotin-tagged 15-deoxy-Δ12,14-Pros-
taglandin J2. (A) The chemical structure of bt-15d-PGJ2 showing the electrophilic
carbons (indicated by asterisks), a ﬁve-carbon linker region ﬂanked by amide
bonds, and a biotin tag. (B) Recombinant Rac1 was reacted with either vehicle (0:1)
or 1:1 M ratio of bt-15d-PGJ2:rRac1 for 1 h at room temperature. Modiﬁed rRac1
was detected by Western blot analysis for biotin. Total rRac1 was analyzed by
Coomassie stain. (C) Recombinant Rac1 (rRac1) was reacted with increasing molar
amounts of bt-15d-PGJ2 at the indicated ratios. Reaction mixtures were loaded
directly onto nitrocellulose via a dot blot apparatus and biotin signal was detected
by Western blot. Biotin density was plotted for each reaction condition (n¼9 in one
independent experiment).carbons (indicated by asterisks), and protein adducts have been
detected using the biotin tag [29,34–38]. Puriﬁed recombinant
Rac1 (rRac1) protein was used to assess modiﬁcation by bt-15d-
PGJ2 in vitro. When rRac1 was treated with equimolar amounts of
bt-15d-PGJ2, a biotin signal was detected by western blot at the
expected molecular weight of rRac1 (21 kDa), whereas no signal
was detected in the untreated rRac1 (Fig. 1B). The treated rRac1
was also applied to nitrocellulose by dot blot in order to determine
the protein modiﬁcation by increasing lipid concentration. Inter-
estingly, rRac1 modiﬁcation by bt-15d-PGJ2 did not increase line-
arly with concentration, since maximal modiﬁcation occurred at
0.5:1 (bt-15d-PGJ2: rRac1) (Fig. 1C).
Identiﬁcation of sites of Rac1 modiﬁcation in vitro by mass
spectrometry
To determine the sites of adduct formation on rRac1, rRac1 was
treated with bt-15d-PGJ2 (1:1 to 1:5 ratio, mol protein:mol lipid)
and then analyzed by a series of high resolution mass spectro-
metry experiments to identify peptide adducts. After reacting
rRac1 with lipid, the tryptic peptides were subjected to liquid
chromatography–tandem mass spectrometry (LC–MS/MS; as de-
scribed in the methods). Fragmentation of peptides was accom-
plished using collision induced dissociation (CID) or high-energy
collision dissociation (HCD) from the same samples in order to
maximize protein coverage. The high resolution LC–MS/MS ana-
lyses were searched by use of the SEQUEST and MASCOT search
algorithms. As expected, the protein was identiﬁed as human Rac1
(UniProt entry P63000) using both search engines (Table S1). Ta-
ble S1 details the peptide fragmentation method, percent cover-
age, and search scores (for potential bt-15d-PGJ2 peptide adducts)
for each reaction condition. These results also indicated mod-
iﬁcation by bt-15d-PGJ2 occurs on two cysteine residues of Rac1.
In order to further investigate these cysteine adducts, high re-
solution broad band mass spectra (MS1) features were examined
and manual interpretation of the MS/MS spectra was done using
theoretical MS/MS peak lists with the Protein Prospector MS
Product tool. Fig. 2 shows tandemmass spectra of parent ions from
carbamidomethyl ([613.321]3þ , top spectrum) and bt-15d-PGJ2
adducts ([803.109]3þ , bottom spectrum) on the C157 containing
peptide (148EIGAVKYLEC157SALTQR163) obtained from the 1:1 re-
action by HCD. Each spectrum shows the relative abundance of the
daughter ions for the respective parent ion. The parent ion,
[613.321]3þ (monoisotopic mass 1836.940 Da), was the exact mass
addition of carbamidomethyl to C157, indicating a carbamido-
methyl adduct (CAM) formed by reaction of Rac1 with iodoace-
tamide. Daughter ions were assigned to the peptide via a se-
quential series of singly charged y-ions, y3–y11 (Fig. 2, top panel).
Additionally, another observed parent ion, [803.109]þ3 (mono-
isotopic mass 2406.306 Da) was the exact mass of bt-15d-PGJ2 to
C157 (Fig. 2, bottom panel). Three daughter ions (y3, y4, and y6)
with similar mass were found from both spectra. Furthermore, the
daughter ions, y6, y7 and y8 indicated that the bt-15d-PGJ2 adduct
occurred on C157 (indicated by the mass gap in the dotted box).
Interestingly, the presence of bt-15d-PGJ2 is conﬁrmed by daugh-
ter ion [627.393]þ1 which corresponds to protonated bt-15d-PGJ2
and is marked by an arrow. Additionally, two *y  ions (*y7 and
*y8 in the insert) correspond to the y7 and y8 peptides without the
bt-15d-PGJ2 adduct. This implies that the fragmentation energy
was sufﬁcient to remove the bt-15d-PGJ2 adduct from the peptide.
A potential adduct on the C178 peptide was identiﬁed in the
MS1 high resolution spectra, but we were unable to verify the
addition by MS/MS. Several proteolytic fragment ions were de-
tected with masses consistent with addition of bt-15d-PGJ2.
Manual interpretation of the MS/MS spectra could only identify
the peptide sequence, but the fragmentation was not sufﬁcient to
Fig. 2. Mass spectrometric identiﬁcation of C157 as a site of rRac1 modiﬁcation. rRac1 was reacted with a 1:1 molar ratio of bt-15d-PGJ2:rRac1 for 1 h at room temperature.
Reaction mixtures were alkylated (carboxyamidomethylated) and subjected to tryptic digestion, separated via HPLC and detected and analyzed via high resolution mass
spectrometry with data dependent selection of m/z for tandem mass spectrometry. The rRac1 peptide containing C157, EIGAVKYLECSALTQR, was observed in both an
alkylated form (top spectrum) and an adducted bt-15d-PGJ2-modiﬁed form (bottom spectrum). The top panel shows the alkylated (carboxyamidomethylated; CAM) peptide
indicated by a series of y-ions. The CAM adduct is indicated on C157. The bottom panel shows bt-15d-PGJ2-adducted peptide indicated by a series of y-ions, showing the mass
gap of Cysþ626.387 Da (bt-15d-PGJ2) within the dotted box. The inset contains a close-up of the region of the m/z spectrum from 650 to 1000. ny7 and ny8 indicate the
absence of the Cysþ626.387 Da mass gap, and the black arrow indicates the m/z of 627.393, consistent with [bt-15d-PGJ2]þ1, as described in Results.
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(data not shown). These results suggest that C178 is likely a target
of adduct formation due to the unique mass of the adduct formed,
but this site could not conclusively be conﬁrmed. The fact that
other sides of adduct formation were not detected does not rule
out these sites, but if they were modiﬁed it was well below our
limit of detection.
Modiﬁcation of Rac1 in endothelial cells
Our group and others have previously demonstrated that 15d-
PGJ2 modiﬁes a discreet electrophile responsive proteome in
multiple cell types [29,39,40]. However, whether 15d-PGJ2 modi-
ﬁes Rac1 in endothelial cells is not known. Primary bovine aortic
endothelial cells (BAECs) were treated for 24 h with increasingconcentrations of 15d-PGJ2. Cytotoxicity was not observed up to
5 mM 15d-PGJ2 (10 fmol/cell), whereas viability decreased to 78%
and 24% at 10 and 20 mM 15d-PGJ2 (20 and 40 fmol/cell), respec-
tively (Fig. S1). These results are consistent with our previous re-
ports of 15d-PGJ2 effects on viability in endothelial cells [30].
Rac1 modiﬁcation in endothelial cells was assessed by afﬁnity
precipitation using the biotin analog of 15d-PGJ2, bt-15d-PGJ2. We
have previously shown that bt-15d-PGJ2 elicits similar cellular
effects as 15d-PGJ2 at similar concentrations in low serum condi-
tions [28]. Fig. 3 shows that total Rac1 levels did not change in
response to the lipid over 4 h (Fig. 3A and B), and Rac1 was only
detected by afﬁnity precipitation in the presence of bt-15d-PGJ2
(Fig. 3A and C), demonstrating that Rac1 is modiﬁed by the lipid.
These data represent the ﬁrst evidence that the GTPase protein,
Rac1, is modiﬁed by 15d-PGJ2 in endothelial cells.
Fig. 3. Modiﬁcation of Rac1 in endothelial cells. BAEC were treated with 10 mM bt-
15d-PGJ2 for 4 h. Lysates were collected and subjected to biotin afﬁnity precipita-
tion. (A) Representative blot for Rac1 showing vehicle or treated lysate and biotin
afﬁnity precipitation eluate (AP:biotin). Panels are taken from the same image and
cropped for ease of presentation. Bar graphs show the average fold change com-
pared with vehicle control in lysate (B) or after biotin afﬁnity precipitation (C)
(7SEM, n¼4; n¼po0.05).
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BAEC were treated with 7.5 mM bt-15d-PGJ2 (15 fmol/cell) for 0.5–
6 h. Rac1 modiﬁcation occurred as early as 0.5 h and increased
over time until 6 h (Fig. 4A). Over the same time frame and
treatment conditions, we sought to determine whether Rac1 ac-
tivity was altered. Interestingly, Rac1 activity increased sig-
niﬁcantly at 1 h post-treatment, and at 2 h began to return to
control levels (Fig. 4B). This activation initially coincided with
formation of Rac1 bt-15d-PGJ2-adduct formation; however, at 4 h
where maximal adducts were observed, the activity was not dif-
ferent to control levels. Taken together, these results suggest cel-
lular regulation of Rac1 activity by bt-15d-PGJ2 occurs at relatively
early time points, and is not directly proportional to adduct for-
mation by bt-15d-PGJ2.
It is known that bt-15d-PGJ2 protein adduct formation in-
creases in a concentration- and time-dependent manner [29].
However, it is not known whether the pattern of protein adducts
changes as a function of bt-15d-PGJ2 concentration. Therefore,
adducts were compared over a range of lipid concentrations (0–
10 mM) in biotin afﬁnity precipitated lysates (see Table S2). In this
method, the amount of lipid adducts afﬁnity precipitated is similar
across a range of concentrations, allowing for a more direct com-
parison of biotin signal patterns at different amounts of the lipid.
No change was observed in the adduct banding pattern by western
blot with increasing amounts of bt-15d-PGJ2 (Fig. S2). Next, Rac1
protein levels were measured after afﬁnity precipitation from cells
treated with bt-15d-PGJ2. Fig. 4C shows increased modiﬁcation of
Rac1 with increasing bt-15d-PGJ2 concentration, although the
treatment did not change the total Rac1 in lysates. Since bt-15d-
PGJ2 has previously been shown to modify cytoskeletal proteins
such as β-actin [38], the degree of Rac1 modiﬁcation was com-
pared to β-actin in our study. Fig. 4C shows that β-actin was also
modiﬁed in an increasing manner up to 10 mM lipid. Bt-15d-PGJ2-modiﬁed Rac1 or β-actin was expressed as a percentage of mod-
iﬁcation from 10 mM then plotted as a function of bt-15d-PGJ2
(Fig. 4D). This plot suggests that Rac1 modiﬁcation increases in a
linear manner up to 1 mM bt-15d-PGJ2, whereas a higher percen-
tage of β-actin protein is modiﬁed by bt-15d-PGJ2 at lower
concentrations.
Since Rac1 activity was altered in response to bt-15d-PGJ2 ad-
duct formation, the effects of the electrophile on endothelial cell
functions which are downstream of Rac1 were determined. First,
endothelial cell migration was monitored in response to 15d-PGJ2
using a scratch assay. Shown in Fig. 5A are representative images
of vehicle and 10 mM 15d-PGJ2-treated BAEC just after scratching
and after 8 h. The migration of endothelial cells was inhibited
signiﬁcantly by 5–10 mM 15d-PGJ2 (Fig. 5B). Next, Rac1 is crucial
for the formation of cellular protrusions (e.g. lamellipodia) such as
those formed by adherent cells just after replating. Therefore, cell
spreading was assessed in response to bt-15d-PGJ2. Fig. 5C shows
representative images 2 h after replating. An example of a spread
cell is marked a white arrow and is shown in the inset having a
protrusion(s) extending from the cellular body. Cells treated with
bt-15d-PGJ2 which had not spread were characterized by a round
shape with a bright halo. The percent cells spread was plotted as a
function of increasing concentrations of bt-15d-PGJ2 in Fig. 5D.
Signiﬁcant inhibition of cell spreading was observed at 10 mM bt-
15d-PGJ2 compared to vehicle control.Discussion
Electrophilic lipids are signaling mediators which elicit a co-
ordinated biological response through the direct modiﬁcation of
protein nucleophiles. It is becoming increasingly clear that elec-
trophilic lipids have additional advantages as signaling mediators
since they form covalent adducts allowing the effect of adduction
to persist and accumulate over time. In particular the electrophilic
lipid, 15d-PGJ2, is a cyclooxygenase 2 (Cox2)-derived electrophilic
lipid which is formed endogenously downstream of PGD2, and has
been described as an anti-inﬂammatory mediator in macrophages
and other cell types [39,41,42]. 15d-PGJ2 has also been found in
atherosclerotic lesions colocalized with Cox2 [41]. Biological re-
sponses of 15d-PGJ2 have been reported to occur due to multiple
mechanisms of action and via direct modiﬁcation of protein thiols
[40]. The formation of these protein adducts has been hypothe-
sized to elicit speciﬁc biological responses via coordinated ad-
duction to the electrophile responsive proteome [43]. Some pre-
viously described members of 15d-PGJ2 modiﬁed proteome are β-
actin, Keap1, and H-Ras. For example, Renedo et al. reported that
two electrophilic lipids, PGA1 and 15d-PGJ2, modiﬁed H-Ras at two
different cysteine residues [44]. Interestingly, modiﬁcation of
H-Ras by 15d-PGJ2 at C184 in the c-terminal hypervariable domain
may alter palmitoylation of the protein and may thereby alter
downstream H-Ras function via interacting with effector proteins
[35]. The fact that H-Ras is modiﬁed by bt-15d-PGJ2 suggests that
other GTPase proteins such as Rac1 may also be targets for the
lipid. In fact, Rac1 is poised to be an important mediator of redox
signaling, due to its role in a wide variety of cellular functions
including reactive oxygen species formation via Nox, cellular mi-
gration, and modulation of downstream signaling pathways.
Rac1 contains seven Cys residues which are highly conserved
across species and therefore, may have important physiological
functions. The C189 residue on Rac1 has been well characterized,
and has been demonstrated to be a site of geranylgeranyl addition.
This modiﬁcation occurs in the endoplasmic reticulum im-
mediately following protein translation as a permanent mod-
iﬁcation, suggesting that this site not available for redox signaling.
It was recently shown that Rac1 is palmitoylated at C178 [16].
Fig. 4. Time- and dose-dependent modiﬁcation of Rac1 in endothelial cells by bt-15d-PGJ2. (A) BAEC were treated with 7.5 mM bt-15d-PGJ2 (þ) or vehicle control () for 0.5,
1, 2, 4, and 6 h, followed by biotin afﬁnity precipitation, and Rac1 was detected by Western blot analysis. (B) Rac1 activity was determined at each time point and normalized
to vehicle control (expressed as percent active Rac1 of the total Rac17SEM; n¼po0.05; n¼3; except at 4 and 6 h where only two replicates were done). (C) Biotin afﬁnity
precipitation was performed on endothelial lysates after treatment with the indicated concentrations of bt-15d-PGJ2. Rac1 and β-actin were detected by Western blot
analysis. The protocol was adjusted to compensate for differences in bt-15d-PGJ2-adducted proteins by increasing the protein load onto the afﬁnity resin (see Methods for
further details). (D) The percent of maximal modiﬁcation of Rac1 and β-actin (determined at 10 mM bt-15d-PGJ2) was plotted for the treatment conditions in the AP:biotin
blots from Panel C.
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lipidation which allows for the transient association of a protein to
detergent resistant membranes and is thereby an important reg-
ulator of localization [45,46]. Interestingly, Navarro-Lérida et al.
further demonstrated that inhibiting palmitoylation by mutation
C178S decreased cellular migration. Another cysteine residue of
Rac1, C18, is located within the guanine nucleotide binding pocket.
This residue has been shown to be modiﬁed by the nonradical
oxidant glutathione, and guanine nucleotide dissociation has been
shown to be increased both S-glutathionylation and by radical
oxidants such as NO2 and superoxide [18,19,47]. C18 was not
found to be modiﬁed by 15d-PGJ2 in our studies. Modiﬁcation at
C18 by 15d-PGJ2 cannot fully be excluded, since tryptic peptides
containing C18 were very large (420 residues in length), and
therefore, the addition of a lipid may have prevented the modiﬁed
peptide from being detected. Although this residue has a relatively
high solvent accessibility compared with other cysteines [47], 15d-
PGJ2 is a relatively large hydrophobic molecule and may be steri-
cally hindered from interaction with residues within the binding
pocket, or may preferentially interact with more hydrophobic re-
gions of the protein.
In this study, we show for the ﬁrst time that C157 and C178 of
Rac1 are modiﬁed by 15d-PGJ2 in vitro. C157 is located in a loop
between the sixth β-strand and the α5 helix (referred to as the G-5
region) [11]. It has recently been shown that mutation of C157, a
residue unique to Rho proteins, impairs the interaction of the Rho
mutant protein with its guanine nucleotide exchange factor [48].
However the precise role of C157 in Rac1 function in endothelial
cells is still not clear. The other modiﬁcation observed in our studywas at C178. This site has been shown to be palmitoylated. Inter-
estingly, previous studies showed that mutation of this residue
inhibited Rac1 localization, reduced spreading and delayed cellular
migration [16]. Under our conditions (7.5 mM bt-15d-PGJ2) we
found that Rac1 activity was increased at 1 h, but returns to
baseline at 2 h (Fig. 4B). The fact that overall protein adducts in-
crease over this time scale (Fig. 4A), suggests that increases in Rac1
modiﬁcation and Rac1 activity are disproportionate. It is intriguing
to speculate based on our recombinant studies, that there may be
two distinct regulatory sites acting as allosteric mediators of Rac1
activity in response to bt-15d-PGJ2 in endothelial cells. While in-
triguing, the studies herein only determine modiﬁcation sites in
the recombinant protein which may not reﬂect modiﬁcations
within the cell. Therefore, experiments to test site speciﬁc mod-
iﬁcation in cells are necessary to correlate Rac1 modiﬁcation and
activity with changes in cell migration or spreading. Ideally, the
role of C157 and C178 modiﬁcation would be investigated using
mutational studies. However, Rac1 Cys-mutations produce non-
functional protein as the previous studies found with the C157R
and C178S mutants [16,48]. Therefore, inhibitory effects of mod-
iﬁcations at these sites are not likely to be interpretable.
The overall effects of 15d-PGJ2 on cells is dependent on several
factors, including amount of lipid, time of exposure, and cell type
and presence of effector proteins. It has been reported that sub-
nanomolar concentrations of 15d-PGJ2 can stimulate cellular mi-
gration of eosinophils in response to a chemoattractant [49]. Other
studies report inhibition of cellular migration in multiple cell types
in response to micromolar levels of 15d-PGJ2 [33,50]. This biphasic
phenomenon of 15d-PGJ2 may be explained by the accumulation
Fig. 5. Endothelial cell migration and spreading in response to 15d-PGJ2 or bt-15d-PGJ2. (A) A conﬂuent monolayer of BAEC was wounded by scratching. Medium was
immediately changed and cells were treated with vehicle or 10 mM 15d-PGJ2. At 4 h after treatment, medium was changed again to remove lipid, and an additional 4 h was
given for cells to migrate (8 h total) before assessing scratch width. Representative images of scratch zone are shown. Cell migration fronts are indicated by white dotted
lines. (B) Cell migration into the cell free zone was determined for 1–10 mM of 15d-PGJ2, and expressed as a percent of cell migration of vehicle-treated cells (7SEM;
*¼po0.05; **¼po0.005; ***¼po0.0005; n¼4). (C) BAEC were treated with vehicle or bt-15d-PGJ2 (1–10 mM) for 4 h. Cells were replated as described in the methods, and
imaged after 2 h for assessment of cell spreading. Representative images (20 ) of cells for vehicle and 10 mM 15d-PGJ2-treated cells are shown. White arrows indicate cells
magniﬁed in the inset. Cell spreading was assessed in four frames per condition. (D) Cells spread were quantiﬁed for each bt-15-PGJ2 concentration (expressed as percent
cells spread 7 SEM; *¼po0.001; n¼8 from two independent experiments).
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as described by Oh et al. [29]. In addition, it is known that adduct
formation occurs on a number of target proteins simultaneously,
and therefore, the observed inhibition of migration and spreading
in response to 15d-PGJ2 may not be solely due to Rac1 modiﬁca-
tion. In fact, as noted in our studies, other cytoskeletal proteins
such as β-actin are sensitive targets for 15d-PGJ2 modiﬁcation
[33,36,51]. Currently, methods of studying electrophile-proteomes
are limited. Based on what we know, cytoskeletal proteins in-
cluding those in the Ras superfamily may be important members
of this proteome.
In conclusion, we have shown that rRac1 residues C157 and
C178 are modiﬁed by bt-15d-PGJ2. Adduct formation with other
cysteine residues, particularly C18 which is a likely target for redox
modiﬁcation, cannot be ruled out by these results. Altogether,
these results suggest that modiﬁcation of Rac1 by electrophilic
lipids may be an additional axis of Rac1 regulation not previously
described, and future studies are warranted.Acknowledgements
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